Today, February 23rd, 2026, Gilead Sciences announced a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, providing Gilead with full ownership of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy for patients with relapsed or refractory multiple myeloma. Arcellx is a clinical-stage biotech company headquartered in Rockville, Maryland, founded in 2014. [Read more…]
The Future of Stem Cell Therapy as Treatment for Autism
Treatment for autism is an increasingly important pursuit, as the Center for Disease Control and Prevention (CDC) estimates:
- 1 in 59 children has been identified with autism spectrum disorder (ASD) [Read article]
- Autism occurs in all racial, ethnic, and socioeconomic groups. [Read article]
- Studies in Asia, Europe, and North America have identified ASD to have a prevalence rate of between 1% and 2%. [Data table]
With autism spectrum disorder (ASD) affecting between 1-2% of the population, the condition is becoming of increasing importance and a treatment for autism is becoming a highly sought-after medical breakthrough.
Longevity Medical Institute® Opens Federally Licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory in Los Cabos
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 3, 2026 — Longevity Medical Institute® today announced the opening of its federally licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory, further expanding what is now one of the most comprehensive regenerative and advanced diagnostic medical campuses in Los Cabos. [Read more…]
BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BOTHELL, Wash. and Cambridge, UK, February 12, 2026 —BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing. [Read more…]
Nucleus Biologics Launches Krakatoa® K500: A Pod-Based, On-Demand Media and Buffer Manufacturing System Transforming Scale Bioproduction
-
Produces 35–500 liters of sterile media and buffers on demand at point-of-use, reducing cost, complexity, and lead times
-
Pod-based, closed single-use system with integrated analytics, QR-code-driven execution, and automated digital batch records to support GMP-compliant manufacturing
San Diego, CA — February 10, 2026 — Nucleus Biologics, a leading provider of custom cell culture solutions and manufacturing technologies for advanced therapies, today announced the launch of Krakatoa® K500, the first bioreactor-scale, pod-based media and buffer manufacturing system designed to deliver sterile solutions on demand and at point-of-use. The system enables the co-location of cell culture media and buffer manufacturing and bioproduction. [Read more…]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 63
- Next Page »